Natural History of Prostatism: Longitudinal Changes in Voiding Symptoms in Community Dwelling Men-Reference-Cited by-同舟云学术

Natural History of Prostatism: Longitudinal Changes in Voiding Symptoms in Community Dwelling Men

Published:1996-02 Issue:2 Volume:155 Page:595-600
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Jacobsen Steven J.¹,Girman Cynthia J.¹,Guess Harry A.¹,Rhodes Thomas¹,Oesterling Joseph E.: Lieber¹

Affiliation:

1. Departments of Health Sciences Research (Section of Clinical Epidemiology) and Urology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, Merck Research Laboratories, Blue Bell, Pennsylvania, and Michigan Prostate Institute and University of Michigan, Ann Arbor, Michigan.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference27 articles.

1. Graves, E.J.: National Hospital Discharge Survey: Annual Summary, 1991. Vital Health Stat., series 13, number 114, 1993.

2. Schappert, S.M.: National Ambulatory Medical Care Survey: 1989 Summary. Vital Health Stat., series 13, number 110, 1992.

3. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States;Jacobsen;Arch. Intern. Med.,1995

4. Why pressure-flow studies should be optional and not mandatory studies for evaluating men with benign prostatic hyperplasia;McConnell;Urology,1994

5. The development of human benign prostatic hyperplasia with age;Berry;J. Urol.,1984

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility of minimally invasive therapies vs pharmacotherapy as initial therapy for benign prostatic hyperplasia: A Canadian healthcare payer perspective;Canadian Urological Association Journal;2022-12-06

2. Is Bladder Outlet Obstruction Diagnosis with Uroflow Parameters Without Urodynamics?;The Journal of Tepecik Education and Research Hospital;2022-08-22

3. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study;Prostate Cancer and Prostatic Diseases;2022-06-10

4. Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis;BMC Urology;2022-05-13

5. Benign Prostate Hyperplasia;Encyclopedia of Gerontology and Population Aging;2021